Összesen 2 találat.


001-es BibID:BIBFORM072903
035-os BibID:(cikkazonosító)e0194166 (WOS)000428603100051 (Scopus)85044720189
Első szerző:Kovács György (belgyógyász, gasztroenterológus)
Cím:Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients / Gyorgy Kovacs, Nora Sipeki, Boglarka Suga, Tamas Tornai, Kai Fechner, Gary L. Norman, Zakera Shums, Peter Antal-Szalmas, Maria Papp
Megjegyzések:Background & aimsTo determine the prognostic potential of classic and novel serologic antibodies regarding unfavorable disease course in a prospective ulcerative colitis (UC) patient cohort, since few and conflicting data are available in the literature regarding this matter.Methods187 consecutive patients were studied prospectively (median follow-up: 135 months) from a single referral IBD center in Hungary. Sera were tested for different IgA/IgG type autoantibodies (anti-neutrophil cytoplasmic [ANCA], anti-DNA-bound-lactoferrin [anti-LFS], anti-goblet cell [anti-GAB] and anti-pancreatic [PAB: anti-CUZD1 and anti-GP2)]) by indirect immunofluorescence technique and for anti-microbial (anti-Saccharomyces cerevisiae [ASCA] IgG/IgA and anti-OMP Plus? IgA) antibodies by enzyme-linked immunosorbent assays.ResultsA total of 73.6%, 62.4% and 11.2% of UC patients were positive for IgA/IgG type of atypical perinuclear-ANCA, anti-LFS and anti-GAB, respectively. Occurrences of PABs were 9.6%, while ASCA IgA/IgG and anti-OMP IgA were 17.6% and 19.8%, respectively. Antibody status was stable over time. IgA type PABs were more prevalent in patients with primary sclerosing cholangitis (37.5% vs. 4.7% for anti-CUZD1 and 12.5% vs. 0% for anti-GP2, p<0.001 for both). IgA type ASCA and anti-CUZD1 antibodies were associated with higher risk of requirement for long-term immunosuppressant therapy in Kaplan-Meier analysis (pLogRank <0.01 for both). However, in multivariate Cox-regression analysis only ASCA IgA (HR: 2.74, 95%CI: 1.46?5.14, p<0.01) remained independent predictor. UC-related hospitalization due to disease activity was only associated with multiple antibody positivity (for 3 or more; HR 2.03 [95% CI: 1.16?3.56]; p = 0.013). None of the individual antibodies or their combination was associated with the risk of development of extensive disease or colectomy.ConclusionEven with low prevalence rates, present study gives further evidence to the role of certain antibodies as markers for distinct phenotype and disease outcome in UC. Considering the result of the multivariate analysis the novel antibodies investigated do not seem to be associated with poor clinical outcome in UC, only a classic antibody, IgA subtype ASCA remained an independent predictor of long-term immunosuppressive therapy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Plos One. - 13 : 3 (2018), p. 1-18. -
További szerzők:Sipeki Nóra (1987-) (általános orvos) Suga Boglárka Tornai Tamás István (1984-) (belgyógyász) Fechner, Kai Norman, Gary L. Shums, Zakera Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:OTKA-115818
IOIBD Research Grant (2012-2015)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat


001-es BibID:BIBFORM059587
Első szerző:Lakatos Péter (Semmelweis Egyetem)
Cím:Risk matrix for prediction of disease progression in a referral cohort of patients with Crohn's disease / Peter L. Lakatos, Nora Sipeki, Gyorgy Kovacs, Eszter Palyu, Gary L. Norman, Zakera Shums, Petra A. Golovics, Barbara D. Lovasz, Peter Antal-Szalmas, Maria Papp
Megjegyzések:BACKGROUND: Early identification of patients with Crohn's disease (CD) at riskfor subsequent complications is essential for adapting treatment strategy. Weaimed to develop a prediction model including clinical and serologic markers for assessing the probability of developing advanced disease in a prospectivereferral CD cohort.PATIENT AND METHODS: 271 consecutive CD patients (42.4% males, median follow-up: 108 months) were included and followed-up prospectively. Anti-Saccharomycescerevisiae antibodies (ASCA IgA/IgG) antibodies were determined by enzyme-linked immunosorbent assay (ELISA). The final analysis was limited to patients withinflammatory disease behaviour at diagnosis. The final definition for advanceddisease outcome was having intestinal resection or disease behaviour progression.RESULTS: ASCA (IgA and/or IgG) status, disease location, and need for earlyazathioprine (AZA) were included in a 3-, 5- and 7-year prediction matrix. Theprobabilities of advanced disease after 5-years varied from 6.2% to 55% dependingon the combination of predictors. Similar findings were obtained in Kaplan-Meier analysis, the combination of ASCA, location and early use for AZA was associated with the probability to develop advanced disease (pLogRank<0.001).CONCLUSION: Our prediction models identified substantial differences in theprobability of developing advanced disease in the early disease course of CD.Markers identified in this referral cohort were different from those previouslypublished in a population-based cohort suggesting that different predictionmodels should be used in referral setting.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
ASCA; Crohn's disease; azathioprine; disease progression; referral cohort; serologic antibodies
Megjelenés:Journal of Crohn's & colitis. - 9 : 10 (2015), p. 891-898. -
További szerzők:Sipeki Nóra (1987-) (általános orvos) Kovács György (1982-) (belgyógyász, gasztroenterológus) Pályu Eszter (1983-) Norman, Gary L. Shums, Zakera Golovics Petra Anna Lovász Barbara Dorottya Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Rekordok letöltése1